...
首页> 外文期刊>Environmental toxicology and pharmacology >Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning
【24h】

Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning

机译:纳米α-酮戊二酸雾化制剂的开发及其在健康人类氰化物中毒中的药代动力学和安全性评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Development of nano alpha-ketoglutarate (A-KG) nebulization formulation for neutralization of inhaled cyanide ion toxicity. Objectives of the present study were to (a) develop a novel A-KG nebulization formulation against cyanide poisoning, particularly hydrogen cyanide gas (b) validate its respiratory fraction in vitro and in vivo, and (c) create its pharmacokinetic data in human volunteers. The formulation was optimized on the basis of particle size of aerosolized droplets after nebulization in 6 volunteers. Gamma scintigraphy was used to quantify total and regional lung deposition of nebulized A-KG after radiolabeling it with Technetium-99m. The formulation was optimized using 30% ethanol-saline with particle size in the range of 300-500 nm. In vitro and in vivo studies showed that drug nebulization resulted in a significant respirable fraction of 65 ± 0.6% with whole lung deposition of 13 ± 1%. Human pharmacokinetic data was derived in 6 healthy human volunteers with peak serum concentration (C_(max)) of 39 ± 3 M-3μg/ml, while the area under curve (AUC) after inhalation was 376 ± 23 μg×h/ml indicating that the drug was rapidly and completely absorbed when targeted directly to lungs. Significant lung deposition of A-KG was achieved with the developed formulation. The formulation appears to have several advantages, including the potential of neutralizing inhaled CN~- ions in the lungs themselves. It is a safe and efficacious procedure, suitable for hospital or ambulance use in accidental cyanide poisoning cases, or as a preventive approach for fire-rescue teams.
机译:纳米α-酮戊二酸(A-KG)雾化配方的开发,用于中和吸入的氰化物离子毒性。本研究的目的是(a)开发一种针对氰化物中毒特别是氰化氢气体的新型A-KG雾化制剂(b)在体内和体外验证其呼吸分数,以及(c)在人类志愿者中创建其药代动力学数据。根据6名志愿者雾化后雾化液滴的粒径优化配方。在用Technetium-99m进行放射性标记后,使用伽玛闪烁显像术定量量化雾化的A-KG的全部和局部肺部沉积。使用30%的乙醇盐水溶液优化配方,粒径在300-500 nm范围内。体外和体内研究表明,药物雾化可吸入部分占65±0.6%,全肺沉积占13±1%。人的药代动力学数据来自6位健康的人类志愿者,血清峰值浓度(C_(max))为39±3M-3μg/ ml,而吸入后的曲线下面积(AUC)为376±23μg×h / ml,表明直接针对肺部时,该药物被迅速完全吸收。通过开发的配方,A-KG在肺部显着沉积。该制剂似乎具有几个优点,包括中和肺中吸入的CN-离子的潜力。这是一种安全有效的程序,适用于意外氰化物中毒情况下的医院或救护车使用,或作为消防队的预防措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号